Analyst Research

Report Title Price
ValuEngine Detailed Valuation Report for BAYRY
Provider: ValuEngine, Inc.
$127.00
Buy
Bayer - Finlabo Research Equity Report: Fundamental and Technical Analysis and 6 months performance forecast
Provider: Finlabo SIM Spa
$58.00
Buy
Bayer AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
Bayer AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Bayer AG Phase III Trial Shows Effectiveness Of Fat-Reducing Drug-Reuters


Friday, 1 Feb 2013 05:43am EST 

Reuters reported that Bayer AG said results of two Phase III trials showed ATX-101, an injectable drug to reduce fat deposits under the chin, was effective as a non-surgical treatment. 

Latest Developments for Bayer AG

Latest Key Developments in Pharmaceuticals

Company Quote

Bayer AG
(BAYGn.DE)
84.16
0.25 +0.30%
7:22am EDT